Clinical trial
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
NCT00089635 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00089635 |
|---|---|
| Title | Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer |
| Official title | A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFr Levels of Immunohistochemistry Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Metastases |
| Intervention type | Drug |
| Interventions | Panitumumab |
| Enrollment | 203 |
| Start date | Aug 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Aug 1, 2008 |
| First posted | Aug 11, 2004 |
| Last update posted | Nov 7, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: